[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:histone-lysine-n-methyltransferase-ezh2":3},{"name":4,"total":5,"recruiting":5,"trials":6},"Histone-Lysine N-Methyltransferase EZH2",10,[7,15,22,29,35,41,47,53,59,65],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07028853","This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.",[11],"Phase 3","RECRUITING","2026-08-26T02:18:46.137046Z","2026-07-05T05:32:16.729396Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT07190300","TulmiSTAR-02: A Phase I\u002FII Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)",[19],"Phase 1\u002FPhase 2","2026-08-26T02:16:44.178623Z","2026-07-05T05:32:16.658506Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":27,"content_modified":28},"NCT07104799","Momelotinib During and After HCT in Myelofibrosis",[26],"Phase 1","2026-08-26T02:17:45.190188Z","2026-05-05T02:43:29.498826Z",{"nct_id":30,"title":31,"phases":32,"status":12,"updated_at":33,"content_modified":34},"NCT06313437","Revumenib in Combination With 7+3 + Midostaurin in AML",[26],"2026-08-26T02:16:56.877406Z","2026-05-05T02:43:28.835411Z",{"nct_id":36,"title":37,"phases":38,"status":12,"updated_at":33,"content_modified":40},"NCT04872543","A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)",[39],"Phase 2","2026-05-05T02:43:28.739275Z",{"nct_id":42,"title":43,"phases":44,"status":12,"updated_at":45,"content_modified":46},"NCT04659616","Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia",[26],"2026-08-26T02:15:36.077529Z","2026-05-05T02:43:28.717298Z",{"nct_id":48,"title":49,"phases":50,"status":12,"updated_at":51,"content_modified":52},"NCT06152809","CIML NK Cells With Venetoclax for AML",[26],"2026-08-26T02:15:47.754948Z","2026-05-05T02:43:28.162326Z",{"nct_id":54,"title":55,"phases":56,"status":12,"updated_at":57,"content_modified":58},"NCT03418038","Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia",[39],"2026-08-26T02:15:21.365312Z","2026-05-05T02:43:29.732946Z",{"nct_id":60,"title":61,"phases":62,"status":12,"updated_at":63,"content_modified":64},"NCT06315309","Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant",[39],"2026-08-26T02:16:48.735701Z","2026-05-05T02:43:29.662218Z",{"nct_id":66,"title":67,"phases":68,"status":12,"updated_at":69,"content_modified":70},"NCT04588922","Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML",[19],"2026-08-26T02:17:16.980188Z","2026-05-05T02:43:28.806272Z"]